Research

RSS feed for this section

Will There Ever Be a Drug for Celiac Disease?

imgres

New drugs on the research horizon could spare people with celiac the pain of accidentally eating pizza or pasta. Even with the best intentions, living gluten-free is much easier said than done. It was almost impossible to tell which packaged “gluten-free” foods lived up to their claims until late last year when the U.S. Food […]

CDF Funds FDA GREAT3 Workshop in Washington, D.C.

CDF_Research_4x4in

On March 30-31st, 2015, Celiac Disease Foundation Chief Executive Officer, Marilyn G. Geller, attended the FDA Public Workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3) near Washington, D.C. This landmark conference addressed endpoints and outcome measures for trials for products intended to treat celiac disease and Irritable Bowel Disease. The second day […]

Biopsy Samples and the Diagnosis of Celiac Disease

CDF_Research_4x4in

Those who have the standard clinical symptoms of celiac disease, such as sensitivity to gluten, irritability, abdominal pain, or a positive blood test, may undergo an endoscopy to confirm their diagnosis. During the procedure, doctors take samples of tissue (a biopsy) from the small intestine to see if there is damage or flattening of villi. Under a microscope, a […]

CDF Joins Autoimmune Research Network (ARNet)

CDF_Research_404x404

Celiac Disease Foundation is pleased to announce our participation in the Autoimmune Research Network, known as ARNet. ARNet is a network of autoimmune disease advocacy organizations that will foster research into celiac disease and related autoimmune conditions. In consonance with CDF’s Strategic Plan to increase national awareness of the ramifications of undiagnosed celiac disease, the first goal of […]

FDA Public Workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3), March 30-31, 2015

great-logo-copy1

Celiac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.

Vaccination and Celiac Disease

3.3.5_vaccination

For people with celiac disease, vaccinations tend to work just as effectively as they do for the general population with one notable exception: hepatitis B. Celiac disease testing is recommended for non-responders to the hepatitis B vaccine who are not already diagnosed.